Exchange: STO Sector: Healthcare Industry: Medical Devices
-1.11% SEK0.160
America/New_York / 3 nov 2023 @ 07:59
FUNDAMENTALS | |
---|---|
MarketCap: | 181.75 mill |
EPS: | 0.320 |
P/E: | 0.500 |
Earnings Date: | Feb 19, 2024 |
SharesOutstanding: | 1 133.08 mill |
Avg Daily Volume: | 0.551 mill |
RATING 2023-11-03 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Sell | |
P/E: | Neutral | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.03x |
Company: PE 0.500 | sector: PE 19.76 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.01x |
Company: PE 0.500 | industry: PE 54.10 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
SEK 0.153 - 0.167 ( +/- 4.36%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | SEK0.160 (-1.11% ) |
Volume | 1.452 mill |
Avg. Vol. | 0.551 mill |
% of Avg. Vol | 263.41 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. It designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. The company offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. It also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include Hummingbird Quad ICP monitoring with drainage (H610), and Hummingbird Solo ICP monitoring (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. It markets and sells its products to hospitals through its direct sales force and a network of distribution partners. IRRAS AB (publ) was incorporated in 2011 and is headquartered in Stockholm, Sweden.